Your session is about to expire
← Back to Search
RNA Polymerase I Inhibitor
CX5461 for Cancer
Phase 1
Waitlist Available
Research Sponsored by Canadian Cancer Trials Group
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12 months
Awards & highlights
Summary
This trial is testing a new drug called CX5461 on patients with hard-to-treat cancers. The drug works by stopping cancer cells from repairing themselves, which may slow their growth or kill them. The study aims to find a safe dose that doesn't cause severe side effects.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Confirm the recommended phase II dose and schedule of CX5461 in patients with solid tumours
Secondary outcome measures
Assess pharmacokinetics of CX5461
Number and severity of adverse events in patients
Trial Design
1Treatment groups
Experimental Treatment
Group I: CX-5461Experimental Treatment1 Intervention
CX5461 as intravenous infusion on day 1 and day 8 every 4 weeks. A day 1 every 3 weeks schedule may be used if the day 1 and day 8 every 4 weeks schedule is not tolerable
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Pidnarulex
Not yet FDA approved
Find a Location
Who is running the clinical trial?
Canadian Cancer Trials GroupLead Sponsor
127 Previous Clinical Trials
68,263 Total Patients Enrolled
Senhwa Biosciences, Inc.Industry Sponsor
6 Previous Clinical Trials
401 Total Patients Enrolled
Stand Up To CancerOTHER
51 Previous Clinical Trials
40,295 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger